Clinical trial · Observational
Glucagon-like Peptide-1 Receptor PET/CT in GLP-1R Related Disease
NCT06725693CI-TRIAL-00085755recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 9, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260909-000002
Summary
Brief summary (as posted)
To evaluate the potential usefulness of 68Ga/18F-Exendin 4 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various GLP-1R-related disease patients.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| GLP1-R-related Disease | — | UNRESOLVED | — |
| Insulinoma | Pancreatic Insulinoma | ALIAS | 0.90 |
| Positron Emission Tomography | — | UNRESOLVED | — |
| Tumor | Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 18F/68Ga-Exendin 4 | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Single Group Assignment
- description
- Each subject receive a single intravenous injection of 68Ga/18F-Exendin 4, and undergo PET/CT imaging within the specificed time.
- interventionNames
- Diagnostic Test: 18F/68Ga-Exendin 4
Primary outcomes (1)
- measure
- Standardized uptake value (SUV)
- timeFrame
- 30 days
- description
- Standardized uptake value (SUV) of Exendin 4 for each target lesion of subject or suspected primary tumor or/and metastasis
Secondary outcomes (1)
- measure
- Diagnostic efficacy
- timeFrame
- 30 days
- description
- The sensitivity, specificity and accuracy of Exendin 4 PET/CT were calculated.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: \- (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled Exendin 4 PET/CT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee. Exclusion Criteria: \- (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
References
Publications (1)
- DERIVEDYu H, Bao X, Gu Y, Pan M, He Q, Li D, Chen Q, Yao S. Comparison of PET/CT using 68Ga-NOTA-Exendin-4 with 68Ga-DOTATATE, 18F-FDG, and conventional imaging in the localization of insulinomas. Eur J Nucl Med Mol Imaging. 2025 Sep;52(11):4102-4111. doi: 10.1007/s00259-025-07288-x. Epub 2025 Apr 22. PMID 40259061